About Hyasynth Bio
Hyasynth Bio is a company based in Montreal (Canada) founded in 2014 by Zach Wiltshire, Alex Campbell, and Shoham Mookerjee. Hyasynth Bio has raised $11.04 million across 5 funding rounds from investors including Organigram, Anges Québec and SOSV. Hyasynth Bio operates in a competitive market with competitors including IGC Pharma, Hempsana, Pike Therapeutics, Soul Biotech and Nura Lyfe Sciences, among others.
- Headquarter Montreal, Canada
- Founders Zach Wiltshire, Alex Campbell, Shoham Mookerjee
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11.04 M (USD)
in 5 rounds
-
Latest Funding Round
$2.5 M (USD), Series A
Dec 22, 2021
-
Investors
Organigram
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Hyasynth Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Hyasynth Bio
Hyasynth Bio has successfully raised a total of $11.04M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $2.5 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hyasynth Bio
Hyasynth Bio has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Organigram, Anges Québec and SOSV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Angel investment network supporting innovative entrepreneurs in Canada.
|
Locked | Locked | Locked | |
|
Venture capital and accelerator services are provided across multiple sectors.
|
Locked | Locked | Locked | |
|
Provider of cannabis products, brands, and international business development investments
|
Locked | Locked | Locked |
Investor details for Hyasynth Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hyasynth Bio
Investment portfolio details for Hyasynth Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hyasynth Bio
Detailed financials for Hyasynth Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hyasynth Bio Comparisons
Peer comparison for Hyasynth Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hyasynth Bio
Hyasynth Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as IGC Pharma, Hempsana, Pike Therapeutics, Soul Biotech and Nura Lyfe Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products targeting neurological disorders like Alzheimer's are developed.
|
|
| Locked | Locked | Locked |
CBD oil processing solutions from hemp plants are provided.
|
|
| Locked | Locked | Locked |
Developer of psychedelic and cannabinoid therapeutics
|
|
| Locked | Locked | Locked |
Psychedelics, mushrooms, and cannabinoids are developed for mental health treatments.
|
|
| Locked | Locked | Locked |
Delivers comprehensive psychedelic and cannabinoid therapeutics for neurological disorders.
|
Detailed competitors of Hyasynth Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hyasynth Bio
Complete news archive for Hyasynth Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hyasynth Bio
Hyasynth Bio was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Hyasynth Bio is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Hyasynth Bio is a funded company, having raised a total of $11.04M across 5 funding rounds to date.
Developer of cannabinoid products intended to treat neurological disorders. The companys products are made using technologies traditional and modern biology combined with computational insights to develop organisms and to treat multiple sclerosis, epilepsy, Alzheimers diseases, and others.
Hyasynth Bio's top competitors include IGC Pharma, Pike Therapeutics and Soul Biotech.
Hyasynth Bio has 3 investors. Key investors include Organigram, Anges Québec, and SOSV.